Clinical Trial

A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of IBI112 in the treatment of adolescent participants with moderate to severe plaque-type psoriasis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-24.
Status change: Not Yet Recruiting → Recruiting 2025-12-19
Trial Details
NCT Number NCT07265284
Lead Sponsor Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Conditions Psoriasis
Enrollment 104 participants
Start Date 2025-12-03
Primary Completion 2026-09-30 (estimated)
Study Completion 2029-01-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-22